Link Cell Therapies
PrivateLast Round
Series A
Dec 15, 2025
Total Funding Raised
$72M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Link Cell Therapies operates in Healthcare & Life Sciences and is based in South San Francisco, California. Its latest recorded funding round was a Series A round in December 2025.
Link Cell Therapies is a biotechnology company developing next-generation logic-gated CAR-T cell therapies for the treatment of solid and liquid cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Link Cell Therapies Comparables
Compare Link Cell Therapies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Inceptor Bio | 87% | |
| ArsenalBio | 85% | |
| AvenCell | 83% |
For institutional investors. Book with your work email.
Link Cell Therapies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 15, 2025 | ||||
| Seed | May 1, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Link Cell Therapies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Wing Venture Capital | Series A |
| Sherpa Healthcare Partners | Series A |
| Samsara BioCapital | Series A, Seed |
| Johnson & Johnson Innovation – JJDC | Series A |
| Johnson & Johnson Innovation - JJDC, Inc. | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 29, 2026
Monthly visitors increased 58% MoM, from 1.3K to 2K.
- Jun 25, 2026
Grew 17% QoQ, from 24 to 28 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresSep 28, 2026
Link Cell Therapies, Inc names Friedrich Graf Finckenstein as CMO in Sep '26; he is a Roche and Iovance alum.
- hiresSep 28, 2026
Link Cell Therapies, Inc names former SystImmune veteran Jie D'Elia as CEO.
For institutional investors. Book with your work email.
Link Cell Therapies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Link Cell Therapies's valuation, stock price, and market status.
Is Link Cell Therapies a public or private company?
Link Cell Therapies is a private company.
What is the current stock price of Link Cell Therapies?
Link Cell Therapies is a private company, so its shares have no public market price. Caplight tracks Link Cell Therapies's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Link Cell Therapies worth (valuation)?
Valuation information for Link Cell Therapies is not publicly available.
Can I buy Link Cell Therapies stock?
Link Cell Therapies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Link Cell Therapies's last funding round?
Link Cell Therapies's most recent funding round was Series A on December 15, 2025.
Who are the main investors in Link Cell Therapies?
Key investors in Link Cell Therapies include Samsara BioCapital, Johnson & Johnson Innovation – JJDC, Johnson & Johnson Innovation - JJDC, Inc..
Will Link Cell Therapies IPO soon?
No public IPO plans have been announced for Link Cell Therapies.
How can I track Link Cell Therapies secondary market activity?
Caplight tracks bids, offers, and trades in Link Cell Therapies's shares on secondary markets.